Ultragenyx Pharmaceutical Inc. (RARE)

NASDAQ: RARE · IEX Real-Time Price · USD
37.79
-1.28 (-3.28%)
Mar 30, 2023, 12:56 PM EDT - Market open
-3.28%
Market Cap 2.65B
Revenue (ttm) 363.33M
Net Income (ttm) -707.42M
Shares Out 70.22M
EPS (ttm) -10.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 106,655
Open 39.31
Previous Close 39.07
Day's Range 37.68 - 39.44
52-Week Range 33.36 - 85.53
Beta 0.94
Analysts Buy
Price Target 93.39 (+147.13%)
Earnings Date May 3, 2023

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysacc... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2014
Employees 1,119
Stock Exchange NASDAQ
Ticker Symbol RARE
Full Company Profile

Financial Performance

In 2022, RARE's revenue was $363.33 million, an increase of 3.39% compared to the previous year's $351.41 million. Losses were -$707.42 million, 55.8% more than in 2021.

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for RARE stock is "Buy." The 12-month stock price forecast is $93.39, which is an increase of 147.13% from the latest price.

Price Target
$93.39
(147.13% upside)
Analyst Consensus: Buy
Stock Forecasts

News

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird ...

16 hours ago - InvestorPlace

Ultragenyx to Present at Guggenheim's Genomic Medicines and Rare Disease Days

NOVATO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se...

1 day ago - GlobeNewsWire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra...

1 week ago - GlobeNewsWire

Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

Dr. Camille Bedrosian to continue employment as strategic development advisor with the company Dr. Camille Bedrosian to continue employment as strategic development advisor with the company

2 weeks ago - GlobeNewsWire

Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference

NOVATO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

1 month ago - GlobeNewsWire

Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y

Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.

1 month ago - Zacks Investment Research

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.40% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita® revenue of $ 279.4 million and Dojolvi® revenue of $55.6 million

1 month ago - GlobeNewsWire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update

NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...

1 month ago - GlobeNewsWire

Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View

Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.

2 months ago - Zacks Investment Research

Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones

Preliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita® Revenue in Ultragenyx Territories 1 of $257 million to $258 million and Dojolvi® revenue of $55 million to $56 million

2 months ago - GlobeNewsWire

Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

3 months ago - GlobeNewsWire

Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth

Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline.

3 months ago - Zacks Investment Research

Ultragenyx to Present at Piper Sandler Healthcare Conference

NOVATO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

4 months ago - GlobeNewsWire

Ultragenyx Announces Departure of Chief Financial Officer

NOVATO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Mardi Dier, Chief Financial Officer (CFO) and Executive Vice President, is leaving the co...

4 months ago - GlobeNewsWire

Ultragenyx to Present at Upcoming Healthcare Conferences

NOVATO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

5 months ago - GlobeNewsWire

Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y

Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

5 months ago - Zacks Investment Research

Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.11% and 8.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update

NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...

5 months ago - GlobeNewsWire

Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR

NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), a biopharmaceutical company focused on the develo...

7 months ago - GlobeNewsWire

Ultragenyx to Participate at Citi BioPharma Conference

NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se...

7 months ago - GlobeNewsWire

Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA®▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

TOKYO, Japan--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypoph...

7 months ago - Business Wire

Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

8 months ago - Zacks Investment Research